BTK and non-Hodgkin lymphoma: In human haematological malignancies, BTK is abundantly expressed and activated in malignant cells from patients with B-cell multiple myeloma11, acute myeloid leukemia (AML)12, chronic lymphocytic leukemia (CLL)13, and non-Hodgkin's lymphoma (NHL)14, 15.